Skip to Main Content

INFORMATION FOR

Geoffrey Chupp, MD

Professor of Medicine (Pulmonary); Director, Yale Center for Asthma and Airways Disease (YCAAD), Pulmonary, Critical Care & Sleep Medicine; Director, Pulmonary Function Laboratory, Yale-New Haven Hospital, Pulmonary, Critical Care & Sleep Medicine

Contact Information

Geoffrey Chupp, MD

Lab Location

Office Location

Mailing Address

  • Pulmonary, Critical Care & Sleep Medicine

    PO Box 208057, 300 Cedar Street

    New Haven, CT 06520-8057

    United States

Research Summary

The YCAAD research program focuses on understanding the mediators and mechanisms underlying the development of asthma and other airways diseases with a focus on patients with more severe disease. Our goals are to understand the pathogenesis of asthma, develop novel clinical tests to enhance the treatment of patients with asthma, and ultimately develop novel treatments and potential cures for asthma.

Specialized Terms: Pathogenesis of airway diseases with a focus on asthma and asthma severity; Chitinases in the development and severity of asthma; Expression and genotype-phenotype relationships of novel inflammatory molecules

Extensive Research Description

Yale Center for Asthma and Airways Disease (YCAAD) Research Program

Yale-New Haven Hospital is the largest referral center in the state and YCAAD is the only dedicated adult asthma center in the region. This active, rapidly growing center receives over 3000 visits a year and is the hub of the clinical/translational research program at Yale. Dr. Geoffrey Chupp, has directed YCAAD and developed a clinical research protocol, The Mechanisms and Mediators of Asthma and COPD (HIC 12268), that has recruited over 400 airway disease subjects to donate specimens to the YCAAD sample repository and participate in YCAAD research activities. The evolution of this research protocol, dovetailed with the clinical program, is a unique system that efficiently recruits subjects into clinical study protocols. These subjects have been recruited in YCAAD and are drawn from a large population of patients that continue to visit the center on a regular basis for long term care of their asthma. This allows for repeat sampling, thus enabling our active pursuit of longitudinal studies. In addition, many of these patients are seen during exacerbations in YCAAD or Yale-New Haven Hospital where exacerbation samples can be taken. From this protocol has grown a large sample repository of clinical and physiologic data, DNA, plasma and lung specimens from asthmatics that are stable or flaring (including the intensive care unit). All of this data is uploaded into a web-based database so that information enters the system in real-time.

YKL-40 Expression is Elevated in the Circulation and Lung of Severe Asthmatics

Once we had established the YCAAD research protocol and recruited an adequate number of patients, we began to search for clinically-practical biomarkers for asthma, focusing on the chitinase-like protein, YKL-40, based on the fact that its murine homologue is induced by interleukin (IL)-13 and it is measurable in the serum. We hypothesized that YKL-40 expression would be increased in asthmatics compared to normal individuals. We also hypothesized, although asthma is traditionally considered an organ-specific disease, that YKL-40 levels in the peripheral circulation would discriminate asthmatic severity. YKL-40 was readily appreciated in the serum from normal volunteers and was significantly higher in the serum from asthmatics [median (interquartile range) 58.3 ng/ml (40.0-73.3) versus 69.7 (40.0-107.1), P=0.02]. Importantly, YKL-40 levels increased with disease severity, with the highest levels observed in refractory asthmatics, compared to moderate and mild asthmatics, respectively (P for trend = 0.003). The median (interquartile range) YKL-40 level in mild asthmatics was 49.11 ng/ml (36.7-94.2), 68.43 ng/ml (38.0-88.0) in moderate asthmatics, and 77.0 (44.6-158.4) in severe asthmatics.
Based on the findings above, it was clear that circulating YKL-40 levels are elevated in asthmatics and, importantly, in severe asthmatics. The levels of YKL-40 also correlated with the expression in the lung and physiologic and pathologic measurements of airway remodeling. This suggested an important role for YKL-40 in the pathobiology of asthma, however, it remained unclear where YKL-40 played its part in the causal pathway and/or does it play a role in modulation of the asthmatic inflammatory response? To address this critical question in humans we hypothesized that genetic variation in the YKL-40 gene (CHI3L1) would influence circulating YKL-40 levels and would be associated with asthma. We thus pursued studies in collaboration with Dr. Carole Ober at the University of Chicago. In these studies, three additional asthma populations were examined, a well characterized founder population of European descent--the Hutterites (a related 13-generation, 1,623-person pedigree), 3 outbred Caucasian populations from the Childhood Origins of ASThma (COAST) birth cohort study, and 2 outbred asthma case-control populations from Freiberg Germany, and Chicago. These studies confirmed our findings in the YCAAD cohort and demonstrated that a polymorphism in the core promoter region of the CHI3L1 gene is associated with YKL-40 levels and with asthma, lung function and bronchial hyperresponsiveness. Now that we have confirmed that CHI3L1 is important in the pathogenesis of asthma, through the molecular phenotyping of lung disease grant Dr. Chupp is the Principle Investigator of, we will begin to dissected the pathobiologic differences in gene expression between individuals with different CHI3L1/YKL-40 genotypes and phenotypes and the impact that these changes have on the risk of asthma and asthma severity. Below is a brief description of the recently awarded phenotyping grant that will study 200 asthmatics for the next two years and will simultaneously measure genome-wide expression of genes in the blood and induced sputum using novel techniques developed in Dr. Chupp’s lab.

Molecular Phenotpying in Asthma Severity and role of Chitinase-3-Like-1 and YKL-40 Genotypes/Phenotypes (RO1-08-006)

We have developed a detailed clinical protocol and will be bringing patients into YCAAD for simultaneous blood and induced sputum sampling with a goal of furthering our understanding of severe asthma and the role of chitinases in asthma. Thus far, the human studies showed that YKL-40 is expressed in exaggerated quantities in the serum of asthma and correlates positively with asthma severity and airway remodeling, but inversely with lung function in multiple asthma populations. The genetic studies demonstrated that YKL-40 levels are associated with a functional polymorphism in the promoter of the CHI3L1 gene and with asthma status, bronchial hyperresponsiveness, and inversely with lung function. Therefore, YKL-40 is not only elevated in asthma, but also appears to part of the pathogenesis of asthma, at least in some patients. Another important observation we have made from these data is that the rs4950928 CC genotype is associated with the highest levels of circulating YKL-40 and nearly all these individuals are severe asthmatics. Furthermore, the frequency of the CC genotype increases with greater asthma severity. Lastly, using a strategy outlined in this proposal to evaluate gene transcription in the circulation, we have found (consistent with all our other results) that CHI3L1 gene expression is elevated in peripheral blood cells in asthmatics compared to controls and that GWAS analysis of individuals with high expression levels of CHI3L1 have identified a number of novel genetic associations will be investigated/validated with collaborators in other asthma populations. We have also demonstrated that relatively small changes in protein and gene expression in the circulation, while at first glance may seem unimportant biologically, when properly validated can identify novel molecules related to asthma pathogenesis. We believe that examining asthma severity using a similar strategy (relative to rs4950928 genotype, YKL-40 levels) will define unique expression profiles, molecules, and polymorphisms that will define specific phenotypes of asthma severity. Asthma Severity YKL-40 CHI3L1 gene.1. Molecular Phenotyping of Asthma Severity: In this project we are characterizing 200 asthmatics and collecting induced sputum and peripheral blood for genome-wide expression profiling to identify gene profiles that associated with asthma severity and common to both the peripheral blood and lung.

2. Gene expression profiles associated with CHI3L1 genotypes and YKL-40 levels in asthma: From the population described above, we are determining the biologic pathways associated with genetic polymorphisms we have determined are associated with asthma and asthma severity.

3.Expression profiles associated with responsiveness to Xolair. Using the profile we have developed for the gene expression study, we will determine the gene profiles that altered in response to treatment with Xolair.

Coauthors

Research Interests

Asthma; Bronchial Diseases; Bronchiectasis; Ciliary Motility Disorders; Lung Diseases; Respiratory Tract Diseases; Pulmonary Medicine

Selected Publications

  • 117 Interleukin-6 and short-palate lung and nasal epithelium clone 1 fluctuations as sex-specific markers of acute cystic fibrosis exacerbationAyala A, Yin H, Khanal S, Niu N, Nunez M, Chupp G, Laguna T, Britto C. 117 Interleukin-6 and short-palate lung and nasal epithelium clone 1 fluctuations as sex-specific markers of acute cystic fibrosis exacerbation Journal Of Cystic Fibrosis 2022, 21: s69. DOI: 10.1016/s1569-1993(22)00808-6.
  • EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIESCORREN J, WECHSLER M, CHUPP G, AMBROSE C, ROSETI S, HELLQVIST Å, ACKERT J, MARTIN N, COLICE G. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES CHEST Journal 2022, 162: a21-a22. DOI: 10.1016/j.chest.2022.08.018.
  • Endothelial Thrombopoietin Receptor Controls Eosinophil Trafficking in Asthma and Chronic RhinosinusitisKorde A, Haslip M, Ahangari F, Pober J, Chupp G, Manes P, Gonzalez A, Takyar S. Endothelial Thrombopoietin Receptor Controls Eosinophil Trafficking in Asthma and Chronic Rhinosinusitis 2022, a5684-a5684. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5684.
  • Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATORMenzies-Gow A, Bourdin A, Cook W, Ambrose C, Chupp G, Kmita K, Lanos-Ackert J, Colice G. Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR Pneumologie 2022, 76: s12-s13. DOI: 10.1055/s-0042-1747713.
  • Chemoattractant-Receptor Homologous Molecule on Th2 Cells (CRTH2) Regulates Neutrophilic Inflammation in the LungJung E, Howell R, Cohen A, Tsang D, Chupp G, Dela Cruz C, Gautam S, Brewster R, Flint J, Yin H, Ristic N, Cosme Jr C. Chemoattractant-Receptor Homologous Molecule on Th2 Cells (CRTH2) Regulates Neutrophilic Inflammation in the Lung 2022, a2534-a2534. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2534.
  • Sexually Dimorphic Innate Immune Programs of Airway Monocytes in Cystic FibrosisYin H, Li N, Shiner N, Khanal S, Schupp J, Chupp G, Gomez J, Britto-Leon C. Sexually Dimorphic Innate Immune Programs of Airway Monocytes in Cystic Fibrosis 2022, a1984-a1984. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1984.
  • Sex-Based Differences in Sputum Inflammation Markers of Acute Cystic Fibrosis ExacerbationAyala A, Yin H, Khanal S, Niu N, Nunez M, Chupp G, Laguna T, Britto-Leon C. Sex-Based Differences in Sputum Inflammation Markers of Acute Cystic Fibrosis Exacerbation 2022, a1988-a1988. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1988.
  • Inhibition of ABCC1 Decreases cAMP Egress and Promotes Human Airway Smooth Muscle Cell RelaxationCao G, Lam H, Jude J, Karmacharya N, Kan M, Jester W, Koziol-White C, Himes B, Chupp G, An S, Panettieri R. Inhibition of ABCC1 Decreases cAMP Egress and Promotes Human Airway Smooth Muscle Cell Relaxation 2022, a3280-a3280. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3280.
  • The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A StudyChupp G, Heaney L, Pelaia G, Welte T, Almonacid Sanchez C, Lee J, Maxwell A, Price R, Jakes R, Alfonso Cristancho R, Howarth P, Brusselle G. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study 2022, a4836-a4836. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4836.
  • Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe AsthmaChupp G, Lee J, Liu M, Schleich F, Heaney L, Ribas C, Carrillo-Díaz T, Aparicio M, Moragón E, Sanchez-Herrero M, Gardiner F, Alfonso-Cristancho R, Jakes R, Price R, Howarth P. Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma Journal Of Allergy And Clinical Immunology 2022, 149: ab318. DOI: 10.1016/j.jaci.2021.12.019.
  • Le mépolizumab réduit l’utilisation de corticostéroïdes systémiques chez les patients atteints de rhinosinusite chronique avec polypes nasauxChupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Sousa A, Martin N, Yang S, Mayer B, Chan R, Matucci A, Chachuat L. Le mépolizumab réduit l’utilisation de corticostéroïdes systémiques chez les patients atteints de rhinosinusite chronique avec polypes nasaux Revue Des Maladies Respiratoires Actualités 2022, 14: 34-35. DOI: 10.1016/j.rmra.2021.11.508.
  • D011 TEZEPELUMAB EFFICACY ACCORDING TO US OMALIZUMAB ELIGIBILITY: RESULTS FROM THE NAVIGATOR PHASE 3 STUDYIsrael E, Chupp G, Colice G, Cook B, Ambrose C, Roseti S, Hellqvist Å, Llanos-Ackert J. D011 TEZEPELUMAB EFFICACY ACCORDING TO US OMALIZUMAB ELIGIBILITY: RESULTS FROM THE NAVIGATOR PHASE 3 STUDY Annals Of Allergy Asthma & Immunology 2021, 127: s14-s15. DOI: 10.1016/j.anai.2021.08.049.
  • D010 CAPTAIN STUDY: EFFECTS OF BASELINE IGE LEVELS ON TRIPLE THERAPY RESPONSE IN INADEQUATELY CONTROLLED ASTHMAOppenheimer J, Abott C, Chang S, Chupp G, Crawford J, Mannino D, Win P. D010 CAPTAIN STUDY: EFFECTS OF BASELINE IGE LEVELS ON TRIPLE THERAPY RESPONSE IN INADEQUATELY CONTROLLED ASTHMA Annals Of Allergy Asthma & Immunology 2021, 127: s14. DOI: 10.1016/j.anai.2021.08.048.
  • VARIATIONS HIGHLIGHTED IN HYPERLOCAL HEATMAPS CAN ADDRESS UNMET NEED AND ALLOCATION OF RESOURCES IN COPDChupp G, Feigler N, Gandhi H. VARIATIONS HIGHLIGHTED IN HYPERLOCAL HEATMAPS CAN ADDRESS UNMET NEED AND ALLOCATION OF RESOURCES IN COPD CHEST Journal 2021, 160: a1796-a1797. DOI: 10.1016/j.chest.2021.07.1630.
  • INCREASED CYTOKINE LEVELS DEFINE THE AIRWAY OF STABLE CYSTIC FIBROSIS PATIENTS COMPARED TO HEALTHY CONTROLSZielonka J, Khanal S, liu Q, Cohn L, Chupp G, Britto C. INCREASED CYTOKINE LEVELS DEFINE THE AIRWAY OF STABLE CYSTIC FIBROSIS PATIENTS COMPARED TO HEALTHY CONTROLS CHEST Journal 2021, 160: a1450-a1451. DOI: 10.1016/j.chest.2021.07.1327.
  • RAPID IMPROVEMENT IN MORNING AND EVENING PEAK EXPIRATORY FLOW IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA TREATED WITH TEZEPELUMABIsrael E, Ambrose C, Hunter G, Cook W, Llanos-Ackert J, Ponnarambil S, Chupp G. RAPID IMPROVEMENT IN MORNING AND EVENING PEAK EXPIRATORY FLOW IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA TREATED WITH TEZEPELUMAB CHEST Journal 2021, 160: a34-a36. DOI: 10.1016/j.chest.2021.07.077.
  • EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDYChupp G, Menzies-Gow A, Ambrose C, Cook W, Kmita K, Lindsley A, Llanos-Ackert J, Colice G, Lugogo N. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY BASELINE BMI IN THE NAVIGATOR STUDY CHEST Journal 2021, 160: a37-a40. DOI: 10.1016/j.chest.2021.07.078.
  • Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATORKorn S, Bourdin A, Chupp G, Colice G, Ambrose C, Kmita K, Llanos-Ackert J, Molfino N, Cook B. Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR 2021, oa1198. DOI: 10.1183/13993003.congress-2021.oa1198.
  • Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATORBourdin A, Menzies-Gow A, Chupp G, Ambrose C, Kmita K, Llanos-Ackert J, Colice G, Cook B. Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR 2021, oa1484. DOI: 10.1183/13993003.congress-2021.oa1484.
  • Efficacy of tezepelumab in adolescents with severe, uncontrolled asthmaIsrael E, Menzies-Gow A, Chupp G, Ambrose C, Cook B, Hunter G, Llanos-Ackert J, Downie J, Colice G. Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma 2021, oa1490. DOI: 10.1183/13993003.congress-2021.oa1490.
  • CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABAKerstjens H, Abbott C, Boulet L, Chang S, Chupp G, Crawford J, Hanania N, Nathan R, Oppenheimer J, Pizzichini E, Sagara H, Busse W. CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA 2021, pa3386. DOI: 10.1183/13993003.congress-2021.pa3386.
  • Sputum Inflammation Markers as Predictors of Acute Exacerbations in Cystic FibrosisZielonka J, Khanal S, Niu N, Slade M, Chupp G, Britto-Leon C. Sputum Inflammation Markers as Predictors of Acute Exacerbations in Cystic Fibrosis 2021, a4252-a4252. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4252.
  • Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 StudyCorren J, Bourdin A, Chupp G, Israel E, Ambrose C, Llanos Ackert J, Kmita K, Cook B, Colice G, Menzies-Gow A. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study 2021, a1198-a1198. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1198.
  • Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT)Chupp G, Beeh K, Jauhiainen A, Necander S, Brown M, Wählby Hamrén U, Forsman H, Kurdyukova Y, Steele J, Astbury C, Psallidas I. Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT) 2021, a1202-a1202. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1202.
  • Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR StudyBourdin A, Menzies-Gow A, Chupp G, Israel E, Hellqvist, Hunter G, Ambrose C, Llanos Ackert J, Colice G, Cook B, Corren J. Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study 2021, a1203-a1203. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1203.
  • Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five YearsBourdin A, Korn S, Chupp G, Cosio B, Arbetter D, Shah M, Garcia Gil E. Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years 2021, a1205-a1205. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1205.
  • Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal PolypsChupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Sousa A, Martin N, Yang S, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps 2021, a1344-a1344. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1344.
  • Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension StudySteinfeld J, Gleich G, Roufosse F, Chupp G, Faguer S, Reiter A, Walz B, Bentley J, Bradford E, Yancey S. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study 2021, a1351-a1351. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1351.
  • International Differences in the Use of Mepolizumab to Treat Severe Asthma - Impact of Reimbursement PoliciesChaudhuri R, Caruso C, Chupp G, Fera T, Koehler T, Schleich F, Valero A, Yang S, Howarth P, Jakes R, Maxwell A, Price R, Alfonso Cristancho R. International Differences in the Use of Mepolizumab to Treat Severe Asthma - Impact of Reimbursement Policies 2021, a1595-a1595. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1595.
  • Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR StudyMenzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Griffiths J, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study Journal Of Allergy And Clinical Immunology 2021, 147: ab249. DOI: 10.1016/j.jaci.2020.12.050.
  • Natural history of disease burden for US patients with asthma vs asthma and COPDBleecker E, Murphy K, Gandhi H, Gilbert I, Zein J, Reibman J, Chupp G. Natural history of disease burden for US patients with asthma vs asthma and COPD 2020, 1397. DOI: 10.1183/13993003.congress-2020.1397.
  • Endothelial Thrombopoietin Receptor Regulates the Severity of Type 2 Inflammation by Controlling Platelet-Eosinophil EngagementKorde A, Ahangari F, Haslip M, Chupp G, Pober J, Gonzalez A, Gomez J, Takyar S. Endothelial Thrombopoietin Receptor Regulates the Severity of Type 2 Inflammation by Controlling Platelet-Eosinophil Engagement 2020, a7635-a7635. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7635.
  • Characterization of Sputum Single Cell Transcriptomes in AsthmaYan X, Liu Q, Adams T, Schupp J, Grant N, Gomez J, Cohn L, Chupp G. Characterization of Sputum Single Cell Transcriptomes in Asthma 2020, a3046-a3046. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3046.
  • Whole Exome Sequencing of Severe Asthma Identifies Novel Gene Association CandidatesWang Z, Shan N, Yan X, Mane S, Gomez J, Chupp G. Whole Exome Sequencing of Severe Asthma Identifies Novel Gene Association Candidates 2020, a1336-a1336. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1336.
  • Blocking YKL-40 (Chitinase-Like Protein Chitinase 3) Reverses IL-13/IL-4-Induced Hyporesponsiveness to Bronchodilators in Human Small Airways and in Human Airway Smooth Muscle CellsKoziol-White C, Parikh V, Chupp G, Panettieri R. Blocking YKL-40 (Chitinase-Like Protein Chitinase 3) Reverses IL-13/IL-4-Induced Hyporesponsiveness to Bronchodilators in Human Small Airways and in Human Airway Smooth Muscle Cells 2020, a1252-a1252. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1252.
  • Assessing Asthma Control in the United States by Examining the Relationships Between Short-Acting Beta 2 -Agonist and Systemic Corticosteroid UseBleecker E, Murphy K, Gandhi H, Gilbert I, Chupp G. Assessing Asthma Control in the United States by Examining the Relationships Between Short-Acting Beta 2 -Agonist and Systemic Corticosteroid Use 2020, a1818-a1818. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1818.
  • Biomarkers, Targeted Therapies, Biologics, and Bronchial ThermoplastyMohan A, Grace J, Mainardi A, Chupp G, Lugogo N. Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty 2019, 123-153. DOI: 10.1007/978-3-030-20812-7_8.
  • Analysis of Sputum Immune Cell Populations and Their Functional Status in AsthmaticsStewart E, Chupp G, Montgomery R, Liu Q, Estrom J. Analysis of Sputum Immune Cell Populations and Their Functional Status in Asthmatics 2019, a2916-a2916. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2916.
  • MicroRNA miR-223 Is Associated with Lung Function Impairment and TH17 Inflammation in AsthmaGomez J, Chen A, Yan X, Cohn L, Chupp G. MicroRNA miR-223 Is Associated with Lung Function Impairment and TH17 Inflammation in Asthma 2019, a2929-a2929. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2929.
  • Cell Lineage Defined by Single Cell Transcriptomics of the Sputum in AsthmaYan X, Liu Q, Mihaljinec A, Gomez J, Cohn L, Chupp G. Cell Lineage Defined by Single Cell Transcriptomics of the Sputum in Asthma 2019, a6085-a6085. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6085.
  • Integration of Sputum eQTL and GWAS Indicates IL-27/EBI3 Pathway Is Associated with Severe AsthmaChu J, Yan X, Liang A, Hu B, Gomez J, Chupp G. Integration of Sputum eQTL and GWAS Indicates IL-27/EBI3 Pathway Is Associated with Severe Asthma 2019, a6088-a6088. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6088.
  • Design of a Phase 2b Dose Finding Study of AZD7594, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator, for the Treatment of AsthmaChupp G, Brown M, Beeh K, Wahlby-Hamren U, Ekelund A, Barkstedt E, Forsman H, Björnsson E, Jauhiainen A, Steele J, Psallidas I. Design of a Phase 2b Dose Finding Study of AZD7594, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator, for the Treatment of Asthma 2019, a1315-a1315. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1315.
  • Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 4 Year Follow-Up Results from a Large Scale Prospective StudyChupp G, Kline J, Khatri S, McEvoy C, Silvestri G, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Olivenstein R, Kahlstrom R, Ryan S, Lawson E, Simoff M, Wahidi M, Lamb C, Ferguson J, Haas A, Hogarth D, Tejedor R, Toth J, Majid A, Fitzgerald J, Enfield K, Grubb G, Laviolette M. Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 4 Year Follow-Up Results from a Large Scale Prospective Study 2019, a2683-a2683. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2683.
  • The Natural History of the Burden of Asthma in the United States by Age and SexBleecker E, Murphy K, Gandhi H, Gilbert I, Chupp G. The Natural History of the Burden of Asthma in the United States by Age and Sex 2019, a7397-a7397. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7397.
  • Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled TriaTrevor J, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Chupp G, Magnan A, Brinke A. Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.912.
  • Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled TrialChupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Trevor J, Magnan A, Brinke A. Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.911.
  • Chest Health-care Provider Perceptions of Electronic CigarettesBaldassarri S, Chupp G, Leone F, Warren G, Toll B. Chest Health-care Provider Perceptions of Electronic Cigarettes CHEST Journal 2016, 150: 1302a. DOI: 10.1016/j.chest.2016.08.1417.
  • MAPKAP kinase 2(MK2) expression is associated with severe asthmaChupp G, Yan X, Nezgovorova V, Grant N, Bradford W, Brophy C, Cohn L. MAPKAP kinase 2(MK2) expression is associated with severe asthma 2016, pa4649. DOI: 10.1183/13993003.congress-2016.pa4649.
  • Proinflammatory cytokines and IP-10 differentiate neutrophilic and eosinophilic asthma subgroupsGueble M, Holm C, Grant N, Ravage-Mass L, Levesh T, Estrom J, Kapagiannidou E, Liu Q, O'Connor P, Gomez-Villalobos J, Cohn L, Chupp G. Proinflammatory cytokines and IP-10 differentiate neutrophilic and eosinophilic asthma subgroups 2016, pa908. DOI: 10.1183/13993003.congress-2016.pa908.
  • Leukotriene C4 Synthase Expression in Sputum Correlates with Disease Severity Amongst Patients with Different Clinical Phenotypes of AsthmaBaker M, Steinke J, Borish L, Chupp G. Leukotriene C4 Synthase Expression in Sputum Correlates with Disease Severity Amongst Patients with Different Clinical Phenotypes of Asthma Journal Of Allergy And Clinical Immunology 2016, 137: ab207. DOI: 10.1016/j.jaci.2015.12.1118.
  • A 43-Year-Old Man With Intravenous Drug Abuse and Recurrent EndocarditisBaldassarri S, Chupp G. A 43-Year-Old Man With Intravenous Drug Abuse and Recurrent Endocarditis CHEST Journal 2013, 144: 296a-296b. DOI: 10.1378/chest.1676394.
  • Characterization Of The Poor Emotional Function Phenotype In AsthmaScatena R, Holm C, He S, Wright P, Sessa W, Cohn L, Gomez-Villalobos J, Mitchell A, Chupp G. Characterization Of The Poor Emotional Function Phenotype In Asthma 2012, a3967-a3967. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3967.
  • Airway Macrophage Expression Signatures Associated With Severe Airflow Obstruction In AsthmaGomez J, Perez M, Mitchell A, Holm C, He S, Chupp G. Airway Macrophage Expression Signatures Associated With Severe Airflow Obstruction In Asthma 2011, a4540-a4540. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4540.
  • The Role Of Neurite Outgrowth Inhibitory Protein-B In Poorly Controlled AsthmaScatena R, Chupp G, Perez M, Gomez J, Wright P, Sessa W, Holm C. The Role Of Neurite Outgrowth Inhibitory Protein-B In Poorly Controlled Asthma 2011, a1349-a1349. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1349.
  • Characterization Of Chitinase Activity In Patients With Stable AsthmaPerez M, Gomez J, He S, Holm C, Chupp G. Characterization Of Chitinase Activity In Patients With Stable Asthma 2011, a4334-a4334. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4334.
  • The 24-bp CHIT1 Exon 10 Polymorphism Is Associated With Airway Hyperresponsiveness In A Population Of Autobody Shop WorkersOng P, Wisnewski A, Stowe M, Holm C, He X, Zheng W, Zhang C, Zhao H, Redlich C, Chupp G. The 24-bp CHIT1 Exon 10 Polymorphism Is Associated With Airway Hyperresponsiveness In A Population Of Autobody Shop Workers 2010, a4002-a4002. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4002.
  • Characterization Of Chitinase Activity And YKL-40 Expression In Induced Sputum From Asthmatics: Correlations With Inflammation And Cell Viability And Gene ExpressionGomez J, Perez M, He X, Mitchell A, Holm C, Chupp G. Characterization Of Chitinase Activity And YKL-40 Expression In Induced Sputum From Asthmatics: Correlations With Inflammation And Cell Viability And Gene Expression 2010, a4279-a4279. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4279.
  • Correlations Between The Chitinase-Like Protein YKL-40 And IL-18 After Segmental Antigen ChallengePerez M, Gomez J, He X, Mitchell A, Kelly E, Jarjour N, Chupp G. Correlations Between The Chitinase-Like Protein YKL-40 And IL-18 After Segmental Antigen Challenge 2010, a5605-a5605. DOI: 10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5605.
  • Intensive Care Unit Management of Status AsthmaticusMarshall P, Possick J, Chupp G. Intensive Care Unit Management of Status Asthmaticus Clinical Pulmonary Medicine 2009, 16: 293-301. DOI: 10.1097/cpm.0b013e3181bdff38.
  • Chitotriosidase Activity and YKL-40 Protein Are Increased in Severe Asthma.Crisafi G, Chupp G, Evans M, Sorkness R, Swenson C, Busse W, Jarjour N. Chitotriosidase Activity and YKL-40 Protein Are Increased in Severe Asthma. 2009, a5440. DOI: 10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5440.
  • Chitinase Activity and YKL-40 Expression in Lungs of Children with Persistent Asthma.Vicencio A, Tsirilakis K, Du Z, Zeng W, Kipperman S, Veler H, Chupp G, Goldman D. Chitinase Activity and YKL-40 Expression in Lungs of Children with Persistent Asthma. 2009, a4811. DOI: 10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4811.
  • Biological Mechanism Associated with Asthma Exacerbation Attack as Revealed By Gene Expression Patterns of Peripheral Blood Mononuclear CellsO'Toole M, Bjornsdottir U, Holgate S, Reddy P, Hill A, McKee C, Csimma C, Legault H, Weaver A, Small C, Ramsey R, Ellis D, Burke C, Thompson P, Irving L, Enden J, Chupp G, Wardlaw A, Stahlman J, Raible D, Miller D, Goldman S, Ryan J, Dorner A, Immermann F. Biological Mechanism Associated with Asthma Exacerbation Attack as Revealed By Gene Expression Patterns of Peripheral Blood Mononuclear Cells Journal Of Allergy And Clinical Immunology 2009, 123: s154. DOI: 10.1016/j.jaci.2008.12.576.
  • PREFACECHUPP G. PREFACE Clinics In Chest Medicine 2001, 22: xi. DOI: 10.1016/s0272-5231(05)70054-x.
  • Airway Inflammation and Remodeling in AsthmaZHU Z, LEE C, ZHENG T, CHUPP G, WANG J, HOMER R, NOBLE P, HAMID Q, ELIAS J. Airway Inflammation and Remodeling in Asthma American Journal Of Respiratory And Critical Care Medicine 2001, 164: s67-s70. DOI: 10.1164/ajrccm.164.supplement_2.2106070.

Clinical Trials